France is preparing to launch a secondary COVID-19 vaccination campaign starting Monday, April 20, 2026. While the general public has grown accustomed to a single annual shot—similar to the seasonal flu vaccine—health authorities are implementing a two-pronged approach for the 2025-2026 season to shield the most vulnerable populations before the summer months.
The spring booster is not intended for everyone. Instead, the French Ministry of Health is targeting a specific group of approximately 3.8 million residents who face the highest risk of severe complications. This strategic timing aims to bridge the gap in immunity that often develops between the autumn campaign and the next scheduled rollout.
As a physician and medical writer, I have seen how the unpredictability of respiratory viruses can challenge public health timing. The decision to vaccinate now, despite low current viral circulation, is a preemptive strike based on historical data from previous years, where unexpected summer surges caught the healthcare system off guard.
Who is eligible for the spring booster?
The primary focus of this campaign is the “fragile” population. Eligibility is strictly defined to ensure those with the weakest immune responses receive priority. The target group includes:
- Individuals aged 80 and older.
- Residents of nursing homes (Ehpad).
- Immunocompromised patients.
- Anyone identified as “extremely high risk” based on a shared medical decision between the patient and their care team.
This differs significantly from the broader autumn campaign, which casts a wider net. The fall rollout typically includes adults aged 65 to 79, pregnant women, and younger individuals with chronic health conditions such as obesity, psychiatric disorders, or other long-term illnesses. It also extends to those who live in close contact with vulnerable people.
Despite these priority tiers, the Ministry of Health has clarified that the vaccine remains accessible to anyone who wishes to receive it. Whether a person falls within the high-risk bracket or not, they can seek vaccination through their primary care physician or at a local pharmacy. To remove barriers to access, the vaccination is covered at 100% by the Assurance Maladie.
The logic behind a spring rollout
At first glance, a spring campaign may seem counterintuitive. Current data from Santé publique France, derived from 54 wastewater monitoring stations across the country, indicates that the virus is currently circulating at very low levels. Wastewater surveillance is a critical tool because it provides an objective measure of community prevalence regardless of how many people are actually seeking tests.
However, the Ministry of Health is acting on a lesson learned from the previous year. In 2025, an epidemic wave began in August and peaked in late September—occurring just before the mid-October vaccination campaign began. By the time the autumn shots were available, many high-risk individuals had already been exposed or were unprotected during the surge.
The goal of this April 20 launch is to “boost” protection that naturally declines over several months. What we have is particularly vital for patients with severe respiratory insufficiency. Professor François Vincent, head of the pneumology department at the CHU de Limoges, emphasizes that for elderly patients with compromised lung function, a twice-yearly vaccination schedule is clinically pertinent.
The Haute Autorité de Santé (HAS) has noted that its 2025 guidance remains current for the 2026 period. The agency has previously highlighted the “unpredictable nature” of COVID-19’s evolution, suggesting that the additional protection provided by current vaccines against circulating variants justifies the preemptive approach.
A global comparison of vaccination strategies
France’s approach to the spring booster puts it in a middle ground between the strategies of its European neighbors and the United States. While the target populations may overlap, the execution and uptake vary wildly.
| Country | Spring Recommendation | Primary Target Group | Strategy Note |
|---|---|---|---|
| France | Recommended | 80+ and high-risk | Two campaigns per year for fragile groups. |
| UK | Recommended | 75+, immunocompromised | Higher uptake (approx. 75% of seniors). |
| Germany | Not Recommended | 60+ and high-risk | Single annual dose via STIKO guidelines. |
| USA | Not Recommended | 6 months and older | Broad annual autumn eligibility via CDC. |
In the United Kingdom, the approach is similar to France’s, targeting those over 75 and care home residents. However, the UK sees significantly higher adherence; while approximately 75% of seniors in the UK were vaccinated, France saw only about 15% of its senior population take up the vaccine last autumn.
Conversely, Germany’s Standing Committee on Vaccination (STIKO) and the United States’ Centers for Disease Control and Prevention (CDC) do not currently recommend a spring dose. The US model focuses on a single, broad-reaching annual campaign available to everyone aged six months and older.
Practical steps for those eligible
For those identified as high-risk, the next step is to consult with a healthcare provider to confirm the timing of the dose. Because the vaccine is fully reimbursed, the process is streamlined through pharmacies and medical offices. Patients are encouraged to bring their vaccination records to ensure the booster is administered at the appropriate interval following their last dose.
Disclaimer: This article is provided for informational purposes only and does not constitute individual medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or vaccination.
The next critical checkpoint for France’s vaccination strategy will be the formal review by the Haute Autorité de Santé for the 2026-2027 season, which will determine if the two-campaign model becomes a permanent fixture of the national public health calendar.
Do you have questions about the recent vaccination schedule? Share this article with someone who may be eligible and join the conversation in the comments below.
